Global incidence of hepatocellular carcinoma (HCC) is rising along with its mortality burden, and more than half of the patients require systemic therapy for advanced disease. There is an ongoing ...

Key Takeaways The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed ...

The Food and Drug Administration (FDA) has granted Fast Track designation to amezalpat (TPST-1120) for the treatment of patients with hepatocellular carcinoma (HCC). Amezalpat is an ...

Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

For more information on this research see: Disparities In Hepatocellular Carcinoma Survival By Medicaid-status: a National Population-based Risk Analysis. European Journal of Surgical Oncology ...

Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy. BMC Research Notes, 2024; 17 (1) DOI: 10.1186/s13104-024-07016-y ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press release from the manufacturer.Y-90 resin microspheres (SIR-Spheres, Sirtex ...